Imbruvica
Total Payments
$19.1M
Transactions
36,687
Doctors
6,321
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $25.40 | 1 | 1 |
| 2022 | $7,760 | 22 | 6 |
| 2020 | $12.6M | 8,330 | 1,794 |
| 2019 | $2.6M | 8,074 | 3,129 |
| 2018 | $2.0M | 10,838 | 3,509 |
| 2017 | $1.9M | 9,422 | 3,420 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.1M | 4,525 | 68.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.5M | 1,087 | 13.1% |
| Consulting Fee | $1.1M | 475 | 5.9% |
| Travel and Lodging | $796,515 | 3,149 | 4.2% |
| Food and Beverage | $590,217 | 26,116 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $534,258 | 155 | 2.8% |
| Grant | $364,340 | 11 | 1.9% |
| Education | $97,553 | 1,169 | 0.5% |
Payments by Type
Research
$13.1M
4,525 transactions
General
$6.0M
32,162 transactions
Research Studies & Clinical Trials
Top Doctors Receiving Payments for Imbruvica — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Boston, MA | $26,689 | 35 |
| , MD | Hematology | Springfield, MA | $26,668 | 40 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $25,472 | 53 |
| , MD | Hematology & Oncology | Johnson City, NY | $23,843 | 38 |
| , DO | Hematology & Oncology | Southfield, MI | $22,349 | 36 |
| , M.D., M.S | Internal Medicine | Los Angeles, CA | $22,156 | 19 |
| , M.D | Hematology & Oncology | Lawrenceville, GA | $21,783 | 27 |
| , M.D | Hematology & Oncology | La Jolla, CA | $21,683 | 41 |
| , M.D | Hematology & Oncology | Houston, TX | $21,489 | 35 |
| , MD | Internal Medicine | New York, NY | $21,122 | 29 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $20,994 | 39 |
| , MD | Hematology | Boston, MA | $19,481 | 46 |
| Steven Coutre | — | Palo Alto, CA | $18,696 | 19 |
| , M.D., PH. D | Hematology & Oncology | Palo Alto, CA | $18,350 | 36 |
| , M.D | Hematology & Oncology | Rancho Cucamonga, CA | $18,089 | 27 |
| , MD | Pediatrics | New York, NY | $17,708 | 1 |
| , M.D | Hematology | Hackensack, NJ | $17,606 | 15 |
| , MD | Medical Oncology | Dallas, TX | $17,560 | 25 |
| , MD | Hematology & Oncology | Denver, CO | $16,191 | 49 |
| , MD | Hematology & Oncology | Columbus, OH | $16,118 | 23 |
| , M.D | Medical Oncology | Orange, CA | $16,069 | 23 |
| , MD | Hematology & Oncology | Williamsville, NY | $15,597 | 20 |
| , M.D | Hematology | Coon Rapids, MN | $15,245 | 37 |
| , MD | Internal Medicine | Houston, TX | $15,186 | 30 |
| , M.D | Hematology & Oncology | Troy, MI | $14,999 | 32 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $19.1M
- Total Doctors 6,321
- Transactions 36,687
About Imbruvica
Imbruvica is a drug associated with $19.1M in payments to 6,321 healthcare providers, recorded across 36,687 transactions in the CMS Open Payments database. The primary manufacturer is Pharmacyclics LLC, An AbbVie Company.
Payment data is available from 2017 to 2023. In 2023, $25.40 was paid across 1 transactions to 1 doctors.
The most common payment nature for Imbruvica is "Unspecified" ($13.1M, 68.5% of total).
Imbruvica is associated with 20 research studies, including "PCYC-1142-CA" ($1.8M).